Claim CME Credits*

*CME/CE credits only available to participants that attended the LIVE session on Friday, December 10, 2021.

Webinars

Click the links below to view our presentations:
 

About the MDS Foundation

Stephen Nimer, MD – Sylvester Cancer Center, Miami, FL
Presentation

While the WHO classification of MDS has helped our patients, we shouid now move to a genetically-inspired classification

Elsa Bernard, PhD – Memorial Sloan Kettering Cancer Center, USA
Presentation Slides Q&A

When and how genetic predisposition to MDS should be taken into account in clinical decision making

Luca Malcovati, MD – University of Pavia, Italy
Presentation Slides Q&A

Can Transplantation improve survival rates for older patients with Higher risk MDS?

Ghulam Mufti, DM, FRCP, FRCPath – King’s College London & King’s College Hospital, UK
Presentation Slides Q&A

Case study 1: An elderly patient with MDS, thrombocytopenia, and a cardiovascular comorbidity that requires anticoagulation or antiplatelet therapy

Moshe Mittelman, MD – Tel-Aviv Sourasky Medical Center, Israel
Presentation Slides Q&A

Case study 2: A patient with a myeloid neoplasm and a TP53 mutation

David Sallman, MD – H. Lee Moffitt Cancer Center and Research Institute, Inc., USA
Presentation Slides Q&A

Case study 3: An Anemic Patient with CCUS

Zhuoer Xie, MD, MS – Mayo Clinic, USA
Presentation Slides Q&A

ACTIVITY OVERVIEW

This symposium will discuss a genetically-inspired classification of MDS aimed at improving clinical decision making. The clinical relevance of genetic predisposition to myeloid malignancies will also be analyzed. Allogeneic transplantation is the only potentially curative treatment for MDS but is associated with substantial morbidity and mortality; evidence that transplantation can improve survival rates for older patients with higher-risk MDS will be presented. Finally, you will hear case-based presentations focused on MDS patients with cardiovascular comorbidity, those with TP53 mutation, and anemic patients with clonal cytopenia of undetermined significance (CCUS).

AGENDA TOPICS

• While the WHO Classification of MDS has Helped our Patients, We Should Now Move to a Genetically-Inspired Classification
• When and How Genetic Predisposition to MDS Should be Taken into Account in Clinical Decision Making
• Can Transplantation Improve Survival Rates For Older Patients with Higher-Risk MDS
• An Elderly Patient With MDS, Thrombocytopenia, and a Cardiovascular Comorbidity that Requires Anticoagulation or Antiplatelet Therapy
• A Patient with a Myeloid Neoplasm and a TP53 Mutation
• An Anemic Patient with CCUS

LEARNING OBJECTIVES

• Upon completion of the educational activity, participants should be able to:
• Discuss how to use molecular profiling in for the classification and management of MDS
• Evaluate genetic predisposition in the management of MDS
• Assess the eligibility for allogeneic stem cell transplantation in older patients with MDS
• Discuss how to treat elderly patient with MDS, thrombocytopenia, and a cardiovascular comorbidity that requires anticoagulation or antiplatelet therapy
• Review to treat MDS patients with a TP53 mutation
• Discuss how to treat an anemic patient with CCUS

FACULTY

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Rena Buckstein, MD – Symposium Co-Chair

Head Hematology Site Group
Co-Director of MDS Research Program
Odette Cancer Center
Toronto, Ontario, Canada

Stephen D. Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, USA

Elsa Bernard, PhD

Memorial Sloan Kettering Cancer Center
New York City, NY USA

Luca Malcovati, MD

Associate Professor of Hematology
Department of Molecular Medicine, University of Pavia &
Unit of Precision Hematology, IRCCS S. Matteo Hospital Foundation
Pavia, Italy

Moshe Mittelman, MD

Director, Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv, Israel

Ghulam Mufti, OBE, DM, FRCP, FRCPath, CPath

Professor of Haemato-Oncology
Director of BMS-Celgene & King’s College London Research Programme
King’s College London & King’s College Hospital
Haematological Medicine
London, UK

David Sallman, MD

Assistant Member
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Malignant Hematology Department
Tampa, FL, USA

Zhuoer Xie, MD, MS

Mayo Clinic
Rochester, MN, USA